Core Viewpoint - The article discusses a groundbreaking advancement in artificial vision technology, specifically the PRIMA system, which has successfully restored functional central vision to patients suffering from age-related macular degeneration (AMD) [4][12][26]. Group 1: Technology Overview - PRIMA is a photovoltaic retinal implant that acts as a substitute for light-sensitive cells, allowing for the restoration of vision in patients whose photoreceptors have died while preserving retinal neurons [27][29]. - The device consists of a small implant (2mm x 2mm x 30μm) and special glasses equipped with a camera that captures images and converts them into infrared light, which the implant then processes [29][32]. - Clinical trials have shown that 84% of participants regained functional central vision, with 80% achieving a significant improvement in visual acuity [32][36]. Group 2: Patient Experience - Sheila Irvine, a 70-year-old participant, regained her ability to read after being blind for 15 years due to AMD, highlighting the personal impact of this technology [7][17]. - The study emphasizes the emotional significance of restoring vision, providing patients and their families a chance to reconnect visually [12][13]. Group 3: Clinical Trials and Results - The clinical trial involved 38 patients across 17 clinical sites, with 32 completing the final evaluation [31][32]. - Results indicated an average improvement of 25.5 letters in visual acuity, equivalent to seeing two lines lower on a standard vision test [32][36]. - Despite some initial adverse reactions, 95% of patients experienced resolution of symptoms within two months, and no significant decline in peripheral vision was noted [35][36]. Group 4: Future Prospects - PRIMA has been submitted for regulatory approval in Europe and is undergoing FDA review in the U.S., with plans for a commercial launch next year [38][41]. - The research team is developing next-generation implants and glasses to enhance visual performance, aiming for smaller pixels and color vision capabilities [41][42]. - The company behind PRIMA, Science Corporation, was co-founded by Max Hodak, a former co-founder of Neuralink, and focuses on neuroengineering and vision restoration technologies [43][48].

Core Viewpoint - The article highlights a groundbreaking advancement in artificial vision technology, specifically the PRIMA retinal implant, which has successfully restored functional central vision in patients suffering from age-related macular degeneration (AMD) [2][10][24]. Group 1: Technology Overview - The PRIMA system is a world-first artificial vision research project that utilizes a retinal implant to restore vision by acting as a substitute for light-sensitive cells [6][25]. - The device is a small photovoltaic retinal implant (2mm x 2mm x 30μm) that works wirelessly, powered by light captured through special glasses equipped with a camera [27]. - The system has shown promising results, with 84% of participants recovering functional central vision and 80% achieving a significant improvement in visual acuity [30]. Group 2: Patient Experience - Sheila Irvine, a 70-year-old participant, regained her vision after 15 years of blindness due to AMD, fulfilling her lifelong desire to read again [5][11]. - Prior to the experiment, Sheila described her vision as severely impaired, likening her eyes to "two black discs" [11]. - After the surgery and rehabilitation, she was able to recognize small text, demonstrating the potential of the PRIMA system to significantly enhance quality of life for patients [15][30]. Group 3: Clinical Trials and Results - The clinical trial involved 38 patients across 17 clinical sites in five countries, with evaluations conducted at 6 and 12 months post-implantation [29]. - The results indicated an average improvement of 25.5 letters (approximately 5 lines) in visual acuity for participants [30]. - While some patients experienced temporary adverse reactions, 95% of these symptoms resolved within two months, and there was no significant decline in peripheral vision [32]. Group 4: Future Prospects - The PRIMA system is currently undergoing regulatory approval processes in Europe and the U.S., with plans for a commercial launch in the near future [35]. - Researchers are also developing next-generation implants and glasses to enhance visual performance, aiming for smaller pixels and color vision capabilities [38]. - The project is seen as a significant step towards making "artificial vision" a reality, akin to the advancements made with cochlear implants for hearing [49].